

Now is the time for proven technology that drives scale

A Vineti technology perspective from CEO and Co-founder Amy DuRoss


The underlying medical science behind cell and gene therapies continues to make remarkable progress, even amid clinical enrollment delays due to COVID-19. Scaling out the production and delivery of high-value, deeply personalized products, however, still requires significantly more simplification and standardization if we are to realize the promise of autologous cell therapies, allogeneic therapies, and personalized cancer vaccines for the benefit of many more patients.



Vineti's Personalized Therapy Management (PTM)® platform's role in simplicity and standardization

Our team at Vineti is entirely focused on continuing to expand Vineti's Personalized Therapy Management (PTM) ® platform, the leading digital solution for personalized medicine supply chains. We believe PTM will be crucial to help simplify and standardize how advanced therapies are delivered at scale.

Vineti's PTM: an end-to-end digital platform solution for orchestrating advanced therapy supply chains



As industry analysts have widely noted, complexity is a critical limiting factor for advanced therapies, especially in the areas of manufacturing and supply chain. These complexities have “led to an extremely high cost of goods sold..., hesitation to utilize CAR T beyond end-of-line patients, and patient drop-offs along the treatment journey.”¹ COVID-19 has exacerbated complexity, with one-third of cell therapy companies reporting manufacturing delays or a complete halt to operations in 2020 and 50 percent of CGT companies reporting a reduction in engagement with HCPs, clinical sites, and patients.²

PTM solves for inherent complexity by bringing the best principles and practices of enterprise software to advanced therapies. PTM is a true **enterprise-grade solution**—a common cloud-based digital platform with configurable workflows. **Configuration tools** in PTM offer our customers and partners the ability to build the unique facets of the support their workflows require in a **consistent and singular platform**, without creating new or customized codelines. Configurability means less effort and less long-term risk than custom code, and ensures that our clients are able to scale their workflows with the needs of an evolving and complex therapy. PTM is also **purpose-built** for our industry, and our team has always remained unilaterally focused on the unique challenges presented by personalized therapeutics. **Standards and best practices** are baked into PTM, as are the uniquely rigorous **compliance and patient safety requirements** of CGT. Configuration enables our biopharmaceutical partners to tailor the PTM platform to their brand, while

¹ “Driving the next wave of innovation in CAR T-cell therapies,” McKinsey, 2019. <https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/driving-the-next-wave-of-innovation-in-car-t-cell-therapies>

² “COVID-19 and cell and gene therapy: How to keep innovation on track,” McKinsey, 2020. <https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/covid-19-and-cell-and-gene-therapy-how-to-keep-innovation-on-track>

our industry-leading security safeguards each partner's IP and patient privacy. **Integrations** connect PTM to the rest of the CGT ecosystem—such as Lonza, Cardinal Health, Cryoport and more than a dozen other **Vineti Alliance Network collaborators**.

PTM delivers a modern digital supply chain orchestration platform

Proven patient safety and compliance. Thousands of commercial cell therapy treatments have already been successfully managed via Vineti. CGT's myriad regulations and compliance requirements, which can overwhelm bespoke or generic solutions, are already baked into PTM. State-of-the-art Chain of Identity (COI) and Chain of Custody (COC) tracking and traceability keep each patient journey moving safely and efficiently.

Simpler scale for multiple growth drivers, including regions, facilities, and drug products.

The Vineti platform is already used in hundreds of leading clinical sites to manage advanced therapy patient processes in a safe, compliant, user-friendly manner. The PTM platform supports autologous and allogeneic products from early-phase clinical to commercial, as well as personalized cancer vaccines, in the U.S., E.U., and Asia-Pacific. The platform stays up to date as our still nascent industry grows and changes.

Reduced risk and guesswork with built-in standards. Insights from 70+ years of team CGT experience and a team of industry experts who've managed more than 125,000 doses of cell therapy are baked into PTM. Our team provides standards leadership for our industry. Want to see an example in action? Learn more about **our recommendations for a new patient COI identifier for the personalized medicine era**.

Security and speed via a proven, purpose-built solution. PTM's enterprise-grade platform provides best-in-class security and peace of mind specific to advanced therapies. PTM's purpose built foundation covers core CGT requirements right from the start. Because PTM lives in the cloud, updates are simple. And PTM delivers the data integrity and insights needed for both regulatory reviews and smarter commercial operations.

Simple for multiple, disparate stakeholders to use, with industry-leading user experience.

Vineti's platform has more than 1,000 users and growing, and their insights help keep us ahead of industry needs. Our leading user experience provides a platform that solves workflow complexity, so that CGT stakeholders can simply log into PTM and get to work on behalf of patients.

Advanced therapies need a true standardized platform, not patchwork customized solutions. PTM's enterprise-based approach delivers simplicity and scale, so that cell and gene therapies can reach all patients in need.



PERSONALIZED
THERAPY
MANAGEMENT

The proven digital solution for advanced therapy supply chains

See our PTM platform for yourself. [Contact us to schedule a demo.](#)

ANOTHER REMARKABLE YEAR FOR ADVANCED THERAPIES

- \$10.7B in sector investment in the first half of the year, outpacing investment in all of 2019
- More than 1,000 regenerative medicine companies worldwide
- More than 1,070 advanced therapy clinical trials

Source: *Alliance for Regenerative Medicine, 2020*

ANOTHER YEAR OF COMPANY GROWTH AND SERVICE TO OUR INDUSTRY FOR VINETI

- 3,000+ cell therapy treatments managed
- 15+ biopharmaceutical clients
- 15+ alliance and integration partners
- \$68M Series C (\$35M + \$33M extension)

NEW INVESTORS

- Cardinal Health
- Marc Benioff

NEW BOARD OF DIRECTORS MEMBERS

- Eli Casdin
- Michele Holcomb, Ph.D.



Amy DuRoss is CEO and Co-founder of Vineti. A long-time leader in biotechnology innovation, Amy began her leadership in regenerative medicine as the Co-founder and Executive Director of Proposition 71, California's \$3 billion stem cell research initiative passed in 2004. She has written and spoken widely on standards for advanced therapies, including this [STAT News commentary](#) on the industrialization of personalization.

LET'S CONNECT

- www.vineti.com
- sales@vineti.com
- (415) 704-8730

© 2020 Vineti, Inc.